About the Journal

SKIN is a bi-monthly, peer-reviewed, online medical journal dedicated to providing an enhanced route to disseminate new dermatologic knowledge on all aspects of cutaneous disease.
Read More

Current Issue

Vol. 4 No. 6 (2020): November Issue and Posters Presentations (FC20 Dermatology Conference)

Published: 2020-11-15

In-Depth Reviews

Original Research

Analyzing the Relationship Between Altmetric Score and Literature Citations in the Dermatology Literature

Meredith E Thomley, Ana Preda-Naumescu, Carter J Boyd, Tiffany Mayo

Page 497-505

Development and Validation of a Diagnostic 35-Gene Expression Profile Test for Ambiguous or Difficult-to-Diagnose Suspicious Pigmented Skin Lesions

Sarah Estrada, Jeffrey Shackelton, Nathan Cleaver, Natalie Depcik-Smith, Clay Cockerell, Stephen Lencioni, Howard Martin, Jeffrey Wilkinson, Lauren Meldi Sholl, Michael Berg, Brooke Russell, Olga Zolochevska, Kyle Covington, Aaron Farberg, Matthew Goldberg, Pedram Gerami, Gregory Hosler

Page 506-522

A 35-Gene Expression Profile Test for use in Suspicious Pigmented Lesions Impacts Clinical Management Decisions of Dermatopathologists and Dermatologists

Aaron Farberg, Kelli Ahmed, Christine Bailey, Brooke Russell, Kelly Douglas, Clare Johnson, Olga Zolochevska, Robert Cook, Matthew Goldberg

Page 523-533

An Update on the Global Burden and Socioeconomics of Scabies

Katelyn Urban, Rachel Lynn Giesey, Maria Delost, Gregory Raymond Delost

Page 534-542

Factors Influencing Patient Satisfaction in Dermatology

Abigail Cline, Tamar Gomolin, Bijan Safai

Page 543-547

Research Letters

755-nm Alexandrite Laser for the Treatment of Non-Facial Superficial and Nodular Basal Cell Carcinoma

Valerie Shiu, Margaret Brown, Pavela Bambekova, Jenny Yeh, Jaqueline Brogan, Catherine Kowalewski

Page 548-551

High Demand: Identification of Dermatology Visit Trends from 1991-2016 National Ambulatory Medical Care Surveys

Jade Conway, Bipasha Roy, Lauren Barazani, Albert Wu, Abigail Cline, Janet Moy

Page 552-555

A Cross-Sectional Study on Herpes Zoster Diagnosis in the time of COVID-19

Niki Nourohammadi MPH, Katerina L. Yale MD, Alessandro Ghigi MS, Kai Zheng PhD, Natasha A. Mesinkovska MD, PhD

Page 556-558

Brief Articles

Merkel Cell Carcinoma Presenting as an Indurated Plaque

Margaret Coleman Maxi, Joel Byrne, Ardenne Martin, Pamela Martin

Page 559-562

Palmoplantar Pityriasis Rosea

Aurel Apple, Ann Lin, Angela Kim, Suzanne Rozenberg, Rachel Kushner

Page 571-574

Anti-SAE1 Antibodies and Dermatomyositis: A Case Series of Three Patients

Claire Wilson, Brandon Roman, Kurt Ashack, Iris K Aronson

Page 578-584

Cutaneous Toxicities of PI3K Inhibitors: A Series of Two Cases and Review of the Literature

Simran Arinder Chadha, Jennifer Shastry, Joel Sunshine, Jennifer Choi, Lauren Guggina

Page 585-590

Painful Retiform Purpura with Cutaneous Necrosis

Alfredo Siller Jr., Joseph Jebain, Yomna Amer, Christopher T. Haley, Leon Chen, Stephen K. Tyring

Page 595-598

Primary Cutaneous Mucinous Carcinoma of the Nasal Bridge

Leon Kou, Lily Zhong, Sid Danesh

Page 599-602

Ixekizumab Overdose: A Case Report

Margaret L. Snyder, MD, Mark G. Lebwohl, MD

Page 603-607

A Rapidly Enlarging Solitary Infantile Myofibroma

Stephany Vittitow, Merrick Kozak, Reza Daughtery, Barrett Zlotoff

Page 608-612

Elephantiasis Nostras Verrucosa

Graham H Litchman, Lauren Schwartzberg, Suzanne Friedler, Suzanne Sirota Rozenberg

Page 613-616

Short Communications

Onychomadesis as a Manifestation of Coxsackievirus A6 in an Adult

Alfredo Siller, Joseph Jebain, Mojahed Shalabi, Stephen Tyring

Page 617-619

Eccrine Porocarcinoma Masquerading as Squamous Cell Carcinoma

Drew Kuraitis, Yong Lee, Abida Kadi, Andrea Murina

Page 620-622

Compelling Comments

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

Roflumilast Cream (ARQ-151) 0.15% and 0.3% Improved Burden of Signs and Symptoms in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Leon Kircik, Mark Lebwohl, Kim Papp, Melinda Gooderham, Linda Stein Gold, Zoe Draelos, Steven Kempers, Stephen Tyring, Lorne Albrecht, Marni Wiseman, Laura Ferris, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk

Page s70

Roflumilast Cream (ARQ-151) Improved Itch Severity and Itch-Related Sleep Loss in Adults With Chronic Plaque Psoriasis in a Phase 2b Study

Linda Stein Gold, Mark Lebwohl, Kim Papp, Melinda Gooderham, Leon Kircik, Zoe Draelos, Steven Kempers, David Pariser, Javier Alonso-Llamazares, Darryl Toth, Kathleen Smith, Robert Higham, Lynn Navale, Howard Welgus, David Berk

Page s71

Deucravacitinib (BMS-986165), an Oral, Allosteric Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement and Improves Quality of Life in Patients With Psoriasis

Alan Menter, Andrew Blauvelt, Bruce Strober, Matthew Colombo, Renata Kisa, Sudeep Kundu, Subhashis Banerjee, Craig Leonardi

Page s72

An Oral, Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib (BMS-986165), Reduced Absolute Psoriasis Area and Severity Index in a Phase 2 Trial in Psoriasis

Bruce Strober, Alice Gottlieb, Diamant Thaçi, Luis Puig, Matthew Colombo, Sudeep Kundu, Renata Kisa, Subhashis Banerjee

Page s73

Maximal Use Study of Tapinarof Cream 1% in Subjects with Extensive Plaque Psoriasis

John Jett, Michael McLaughlin, Mark Lee, Lawrence Parish, Glenn Tabolt, Timothy Wilson, Matthew Somerville, Wayne DellaMaestra, Stephen Piscitelli

Page s74

Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Mark Lebwohl, Linda Stein Gold, Bruce Strober, April Armstrong, H Chih-Ho Hong, Leon Kircik, Jennifer Soung, Jeff Fromowitz, Scott Guenthner, Stephen Piscitelli, David Rubenstein, Philip Brown, Anna Tallman, Robert Bissonnette

Page s75

Acne & Rosacea

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race

Fran E Cook-Bolden, Neal Bhatia, Jonathan S Weiss, Neil Sadick, Stephen K Tyring, Eric Guenin, Anya Loncaric, Susan Harris

Page s88

Atopic Dermatitis

The Safety and Efficacy of Roflumilast Cream 0.15% and 0.05% in Atopic Dermatitis: Phase 2 Proof-of-Concept Study

Melinda J. Gooderham, Leon H. Kircik, Matthew Zirwas, Mark Lee, Steven E. Kempers, Zoe D. Draelos, Laura Ferris, Terry M. Jones, Etienne Saint-Cyr Proulx, Robert Bissonnette, Neal Bhatia, Scott T. Guenthner, Robert A. Koppel, Howard Welgus, Charlotte Merritt, Meg Elias, Lynn Navale, Robert C. Higham, Michael Droege, David R. Berk

Page s93

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies

Kim Papp, Jacek C. Szepietowski, Leon Kircik, Darryl Toth, Michael E. Kuligowski, May E. Venturanza, Kang Sun, Eric L. Simpson

Page s95

Efficacy and Safety of Tralokinumab Monotherapy in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from Two 52-Week, Phase 3 Trials (ECZTRA 1 and ECZTRA 2)

Eric Simpson, Andrew Blauvelt, Emma Guttman-Yassky, Margitta Worm, Charles Lynde, Hidehisa Saeki, Yves Poulin, Andreas Wollenberg

Page s96

Efficacy and Safety of Tralokinumab with Concomitant Topical Corticosteroids in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of the ECZTRA 3 Trial

Boni E. Elewski, Matthew J. Zirwas, Richard G. Langley, Andrew F. Alexis, Karen A. Veverka, John Zoidis, Azra Kurbasic, Jonathan I. Silverberg

Page s97

Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Jonathan I. Silverberg, Michael Cork, Andreas Wollenberg, Norito Katoh, Louise Abildgaard Steffensen, Azra Kurbasic, Christina Kurre Olsen, Alexandra Kuznetsova, Marie Louise Østerdal, Andreas Westh Vilsbøll, Mette Deleuran

Page s98

Tralokinumab Improves Clinically Relevant Outcome Measures: A Post Hoc Analysis of ECZTRA 3, A Randomized Clinical Trial in Patients with Moderate-To-Severe Atopic Dermatitis

Stephan Weidinger, Andrew Pink, Juan Francisco, Azra Kurbasic, Christina Olsen, Andreas Vilsbøll, Marjolein de Bruin Weller

Page s100

Dupilumab Provides Acceptable Long-Term Safety and Efficacy in Children Aged ≥ 6 to < 12 Years with Uncontrolled, Severe Atopic Dermatitis

Michael Cork, Diamant Thaçi, Lawrence Eichenfield, Peter Arkwright, Zhen Chen, Mohamed Kamal, John O'Malley, Ashish Bansal

Page s104

Atopic Dermatitis (AD) Disease History With AD Treatment History in a Cohort of AD Patients Treated With Dupilumab From a Real-World Registry (PROSE)

Tien Nguyen, Hermenio Lima, Lindsey Finklea, Haixin Zhang, Daniel Richman, Andrew Korotzer, Shikha Bansal

Page s105

Baseline Characteristics of Atopic Dermatitis (AD) and AD Treatments in a Cohort of Adult AD Patients Initiating Dupilumab in a Real-World Registry (PROSE)

Daniel Shrager, Scott Guenthner, David Cohen, Haixin Zhang, Daniel Richman, Andrew Korotzer, Shikha Bansal

Page s106


Selective Inhibition of Tyrosine Kinase 2 With Deucravacitinib (BMS-986165) Compared With Janus Kinase 1−3 Inhibitors

Anjaneya Chimalakonda, James Burke, Lihong Cheng, Ian Catlett, Aditya Patel, Jun Shen, Ihab Girgis, Subhashis Banerjee, John Throup

Page s108

Review of Mechanisms of Release of Commonly Prescribed Tetracyclines

Pearl Kwong, Hilary Baldwin, Debbie Glaab, Rhonda Schreiber, Emma Hignett

Page s110

Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis

Caroline Robert, Jean Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Dirk Schadendorf, Georgina Long

Page s112


Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents

ZP Rice, LJ Pieretti, A Wheeler, J Payne, KK Gillard, AA Hebert

Page s117

Skin Cancer

Phase I Maximal Use Pharmacokinetic Study of Tirbanibulin Ointment 1% in Subjects with Actinic Keratosis

Regina Yavel, J. Scott Overcash, Jay Zhi, Eva Cutler, David Cutler, Jane Fang

Page s119

Favorable Safety Profile of Tirbanibulin Ointment 1% for Actinic Keratosis: Pooled Results from Two Phase III Studies

Todd Schlesinger, Neal Bhatia, Brian Berman, Ayman Grada, Albert Torra, David Cutler, Mark Lebwohl

Page s120

Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies

Andrew Blauvelt, Steven Kempers, Todd Schlesinger, Edward Lain, Hui Wang, David Cutler, Mark Lebwohl, Jane Fang, Rudolf Kwan

Page s121

Health-Related Quality of Life (HRQL) in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC) Treated with Cemiplimab: Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Michael Migden, Danny Rischin, Medha Sasane, Vera Mastey, Anna Pavlick, Chrysalyne Schmults, Zhen Chen, Alexander Guminski, Axel Hauschild, Denise Bury, Anne Lynn Chang, Guilherme Rabinowits, Sheriff Ibrahim, Israel Lowy, Matthew Fury, Siyu Li, Chieh-I Chen

Page s122

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

Danny Rischin, Nikhil Khushalani, Chryslalyne Schmults, Alexander Guminski, Anne Lynn Chang, Karl Lewis, Annette Lim, Leonel Hernandez-Aya, Brett Hughes, Dirk Schadendorf, Axel Hauschild, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Zhen Chen, Emmanuel Okoye, Israel Lowy, Matthew Fury, Micahel Migden

Page s124

Demographics, Prior Therapies, and Reasons for Cemiplimab Treatment: Prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) Study in Patients with Advanced Cutaneous Squamous Cell Carcinoma

Guilherme Rabinowits, Jade Homsi, Mina Nikanjam, Rhonda Gentry, John Strasswimmer, Suraj Venna, Michael Migden, Sunandana Chandra, Emily Ruiz, Haixin Zhang, Jennifer McGinniss, Alex Seluzhytsky, Jigar Desai

Page s125

Combining DNA and RNA Analyses Enhances Non-Invasive Early Detection of Cutaneous Melanoma

Stepnaie Cullison, Laura Ferris, Zuxu Yao, Claudia Ibarra, Michael Howell, Burkhard Jansen

Page s126


View All Issues